



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

REC'D 14 FEB 2003

WIPG

PC

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02006454.9

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

DEN HAAG, DEN
THE HAGUE,
LA HAYE, LE

21/11/02

BEST AVAILABLE COPY



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation

Anmeldung Nr.:
Application no.:
Demande n°: 02006454.9

Anmeldetag:
Date of filing: 22/03/02
Date de dépôt:

Anmelder:
Applicant(s):
Demandeur(s):
ALTANA Pharma AG
78467 Konstanz
GERMANY

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:
Pantoprazole cyclodextrin inclusion complexes

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:
State:
Pays:

Tag:
Date:
Date:

Aktenzeichen:
File no.
Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:
A61K47/48

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing:
Etats contractants désignés lors du dépôt:

AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE/TR

Bemerkungen:
Remarks:
Remarques:

The applicant's name at the time of filing of the application was as follows: Byk Gulden Lomberg Chemische Fabrik GmbH
The registration of the change has taken effect on: 12-07-2002.

Pantoprazole Cyclodextrin Inclusion Complexes

Technical field

The present invention relates to the field of pharmaceutical technology and describes pantoprazole cyclodextrin inclusion complexes.

Background art

H⁺/K⁺-ATPase inhibitors, in particular pyridin-2-ylmethylsulfinyl-1H-benzimidazoles like those disclosed, for example, in EP-A-0 005 129, EP-A-0 166 287, EP-A-0 174 726 and EP-A-0 268 966 are important in the therapy of disorders originating from increased gastric acid secretion. Examples of active ingredients from this group which are commercially available are 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: omeprazole), 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: pantoprazole), 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: lansoprazole) and 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole (INN: rabeprazole).

WO86/00913 discloses to form a stable complex by mixing and reacting omeprazole with β -cyclodextrin in 96% ethanol and cooling the reactant. WO93/13136 is related to a method for preparing enteric coated oral drugs containing acid-unstable compound, in particular an enteric-coated oral drug prepared in the form of acid-stable dosage unit inclusion complex formed by reacting benzimidazole derivative, acid-unstable compound, with cyclodextrin in alkaline solution. WO9638175 is related to a stabilized composition comprising an antiulcerative benzimidazole compound, particularly a proton pump inhibitor and a branched cyclodextrinic carboxylic acid.

Description of the invention

Surprisingly it has now been found that by reaction of pantoprazole with a cyclodextrin, inclusion complexes are obtained with increased overall solubility for pantoprazole brought about by the formation of soluble pantoprazole-cyclodextrin complexes.

Subject of the present invention is a pantoprazole cyclodextrin inclusion complex.

Pantoprazole in connection with the invention refers to 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole. Pantoprazole is a chiral compound. The term pantoprazole in

1103EPORD02 03022

2

connection with the invention also encompasses the pure enantiomers of pantoprazole and their mixtures in any mixing ratio. Pure enantiomers which may be mentioned by way of example are (-)-pantoprazole and (+)-pantoprazole. Pantoprazole may be present as such or, preferably, in the form of its salts with bases. Examples of salts with bases which may be mentioned are sodium, potassium, magnesium or calcium salts. If pantoprazole is isolated in crystalline form, it may contain variable amounts of solvent. The term pantoprazole therefore also represents according to the invention all solvates, in particular all hydrates, of pantoprazole and its salts.

In a preferred embodiment pantoprazole refers to pantoprazole sodium sesquihydrate (= pantoprazole sodium x 1.5 H₂O), (-)-pantoprazole sodium sesquihydrate or pantoprazole magnesium dihydrate.

Cyclodextrin In connection with the invention preferably refers to α -, β - or γ -cyclodextrin, mixtures of α -, β - or γ -cyclodextrin or derivatives of α -, β - or γ -cyclodextrin. In a preferred embodiment of the invention cyclodextrin refers to β -cyclodextrin (β -CD), hydroxypropyl- β -cyclodextrin (HP β -CD), the sodium salt of sulfobutylether β -cyclodextrin (SB β -CD) or hydroxyethyl- β -cyclodextrin.

The pantoprazole cyclodextrin inclusion complexes may be produced for example by standard procedures for preparation of compound-cyclodextrin inclusion complexes. Such procedures are for example disclosed in WO86/00913, WO93/13138, WO9638175 or by Duchene (in Proceedings of the Fourth International Symposium on Cyclodextrines, 265-276, 1988 by Kluwer Academic Publishers; eds. O. Huber and J. Szejtli). Inclusion compounds are usually prepared in liquid medium, but they can also be obtained in the solid phase. In one embodiment of the invention the inclusion complex is obtained by reacting pantoprazole with the cyclodextrin in a suitable solvent. In a preferred embodiment of the invention the solvent is an aqueous solvent or a solvent which essentially consists of an aliphatic alcohol, preferably ethanol. The inclusion complex may then be obtained by precipitation or freeze drying. In one embodiment the inclusion complex is obtained according to the method described in WO86/00913.

The pantoprazole cyclodextrin inclusion complexes of the invention can then be used as a basis for the production of the administration forms according to the invention. Administration forms according to the invention which may be mentioned, to which the preparations can be processed, are, for example, suspensions, gels, tablets, coated tablets, multicomponent tablets, effervescent tablets, rapidly disintegrating tablets, powders in sachets, sugar-coated tablets, capsules or alternatively suppositories. The excipients which are suitable for the desired administration forms are familiar to the person skilled in the art on the basis of his/her expert knowledge. Due to the increased solubility of pantoprazole in the pantoprazole cyclodextrin inclusion complex administration forms containing such inclusion complex have improved active compound bioavailability properties.

Suitable administration forms are for example disclosed in WO9222284, WO9702020, EP-A-0 244 380, WO96/01623, WO96/01624, WO96/01625 or WO97/25030.

; 1103EPORD02 03022

3

The administration forms according to the invention comprise the pantoprazole of pantoprazole cyclodextrin inclusion complex in the dose customary for the treatment of the particular disorder. The pantoprazole cyclodextrin inclusion complex of the invention can be employed for the treatment and prevention of all disorders which are regarded as treatable or preventable by the use of pyridin-2-ylmethylsulfinyl-1H-benzimidazoles. In particular, the pantoprazole cyclodextrin inclusion complex of the invention can be employed for the treatment of gastric disorders. Administration forms such as tablets contain between 1 and 500 mg, preferably between 5 and 60 mg, of an acid-labile proton pump inhibitor. Examples which may be mentioned are tablets which contain 10, 20, 40 or 50 mg of pantoprazole. The daily dose (e.g. 40 mg of active ingredient) can be administered, for example, in the form of a single dose or by means of a plurality of doses of the tablets of the invention (e.g. 2 x 20 mg of active ingredient).

1103EPORD02 03022

4

EXAMPLE

5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole sodium sesquihydrate β -cyclodextrin inclusion complex

1.73 g of 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole sodium sesquihydrate, 5.67 g β -cyclodextrin and 20 ml of ethanol (96%) are heated to 30 to 32° C and stirred for 15 hours. The mixture is cooled to 10 ° C within 3 hours, filtered and the precipitate washed with ethanol (10 ° C). After drying under reduced pressure the title compound is obtained.

COMPLEXATION STUDIES OF PANTOPRAZOLE WITH CYCLODEXTRINS

Methods: Various solutions of the different cyclodextrins taken into consideration were prepared in phosphate buffer solution pH 7 at known concentrations and used to create saturated solutions of pantoprazole. After equilibration, these saturated solutions were filtered through MFTM membrane filters (pore size 0.45µm), appropriately diluted with phosphate buffer solution and subjected to uv/vis spectrophotometric analysis. The cyclodextrin solutions prepared with phosphate buffer ranged from concentrations of 0% p/v up to 1.8% p/v for βCD, 20% p/v for HPβCD.

Results: In both cases, the solubility of pantoprazole increased markedly with increasing cyclodextrin concentration. In the presence of βCD pantoprazole's solubility rose to a four fold maximum with respect to its solubility in phosphate buffer whereas when equilibrated with HPβCD, pantoprazole showed an outstanding increase in its solubility reaching over seventy times that in phosphate buffer solution.

Conclusions: The phase solubility studies with βCD and HPβCD were both characterised by an overall increase in pantoprazole's solubility brought about by the formation of soluble pantoprazole/cyclodextrin complexes. In the case of βCD phase solubility studies, the increase observed followed a typical A_p pattern commonly described by Higuchi-Connor, indicating the formation of complexes with an order higher than one. Pantoprazole's behaviour with HPβCD also followed a typical Higuchi- Connor's A_p pattern characterised further by an initially gradual increase in solubility.

Complexation studies on pantoprazole, both in its saline form as a sodium salt (PNTNa) and as a free acid (PNTH), were carried out with β-cyclodextrin (β-CD), hydroxypropyl-β-cyclodextrin (HPβ-CD) and the sodium salt of sulfobutylether β-cyclodextrin (SBβ-CD). A second study was carried to define the Phase-solubility behaviour of PNTH when equilibrated with aqueous solutions of β-CD, HPβ-CD and SBβ-CD prepared in phosphate buffer solution (pH 7).

Methods of Sample Preparation

Preparation of PNTH

Pantoprazole sodium salt was used as a starting material. PNTH was obtained via drop by drop acidification of an aqueous solution of the sodium salt with acetic acid (0.1N) until pH 7.5 was reached. The resulting milky white suspension was filtered with use of the Buchner apparatus and the resulting solid was left to dry.

Complexation Studies

Kneading

Inclusion complexes of pantoprazole, both the sodium salt (PNTNa) and the undissociated form (PNTH), with β -cyclodextrin (β -CD), hydroxypropyl- β -cyclodextrin (HP β -CD) and the sodium salt of sulfobutylether β -cyclodextrin (SB β -CD) were prepared via kneading 1:1 and 1:2 molar physical mixtures. A phosphate buffer or a 1:1 hydroethanolic solution were used as binding solutions respectively for the preparation of PNTNa and PNTH.

Freeze Drying

The technique of Freeze-Drying was applied to the preparation of 1:1 molar inclusion complexes of PNTH and PNTNa respectively with HP β -CD.

In preparing the PNTNa: HP β -CD 1:1 molar sample, which was then to be subjected to freeze drying, the exact quantity of HP β -CD was first dissolved in the minimum amount of distilled water necessary (1.5 ml/mg ca) and stirred continuously. The exact amount of weighed PNTNa was then added in small portions. After complete solubilization of the drug, the sample was frozen in liquid nitrogen and freeze dried (-70°C , 760 torr) for 12 hours.

The PNTH: HP β -CD 1:1 molar sample was prepared differently according to the following method. Once again, the exact quantity of HP β -CD was first dissolved in the minimum amount of distilled water necessary (1.5 ml/mg ca) and stirred continuously. The exact amount of weighed PNTH was then added in small portions but its solubilization was helped along by the addition of acetone. The total volume of acetone added in relation to the amount of water used to solubilize HP β -CD was 1:1. The sample was then frozen in liquid nitrogen and freeze dried (-70°C , 760 torr) for 12 hours.

PHASE-SOLUBILITY STUDIES OF PNTH WITH NATURAL AND MODIFIED CYCLODEXTRINS.

The solubility of PNTH in phosphate buffer solution at pH 7 was determined using a previously constructed absorbance vs. concentration calibration curve.

A known amount of PNTH was suspended in cyclodextrin solutions of different concentrations ranging from; 0 to 1.8% (p/v) for β -CD, 0 to 20% (p/v) for H-P β -CD and 0 to 15% (p/v) for SB- β -CD. The resulting suspension was filtered using a PTFE 0.45 μ filter, adequately diluted and then subjected to UV spectrophotometric analysis. The concentration of PNTH in the corresponding sample was then calculated referring to the relevant PNTH calibration curve.

Characterization Techniques**Complexation Studies**

Thermal traces were obtained using a Mettler DSC 821^o module. FTIR spectra were carried out on KBr discs in the 400-4000 cm^{-1} range (Jasco FT-300-IE). The Freeze Dryer used was a Pirani 10 Edwards Modulyo model. Powder X-ray diffractograms were recorded using a Bruker D5005 Diffractometer.

Phase-solubility Studies

UV-VIS spectra were recorded on a Jasco V570 Spectrophotometer.

Results

Phase-solubility Studies

A. Phase-solubility Curve of PNTH with β -CD in Phosphate Buffer Solution pH 7.

The Phase-solubility curve (Figure 1) follows a typical Higuchi-Connor pattern of type A_L. In fact, pantoprazole presents a linear increase in its apparent solubility when equilibrated with solutions of β -CD, reaching up to four times its solubility in phosphate buffer alone (from 0.56 mmol/L up to 2.25 mmol/L).




Figure 1.

B. Phase-solubility Curve of PNTN with HP β -CD in Phosphate Buffer Solution pH 7

Even in this case, the Phase Solubility curve (Figure 2) follows a typically linear Higuchi-Connor pattern. In fact, the increase observed in the apparent solubility of pantoprazole when equilibrated with solutions of HP β -CD, reaches up to 36 times that in phosphate buffer alone (from 0.56 mmol/L up to 17.8 mmol/L).




Figure 2.

C. Phase-solubility Curve of PNTN with SB β -CD in Phosphate Buffer Solution pH 7

In this case, the solubility of pantoprazole increases linearly when equilibrated with solutions of SB β -CD, and the Phase Solubility curve (Figure 3) shows that its apparent solubility increases twenty fold with respect to its value in phosphate buffer alone (from 0.56 mmol/L up to 9.3 mmol/L).




Figure 3.

Complexation Studies of samples prepared by kneading

Differential Scanning Calorimetry (DSC) was first used to characterise both the physical mixtures and the solid phases obtained after wetting and kneading. In none of the cases did we succeed in obtaining an inclusion complex using the technique of kneading. In fact, the DSC traces showed a first broad endothermic peak below 100 °C corresponding to cyclodextrin dehydration, and a second sharp endothermic peak either at 134 °C for PNTNa or at 144 °C for PNTN due to fusion.

Complexation Studies of samples prepared via freeze drying

The samples obtained via freeze drying both had a fluffy white foam-like consistency. Thermal analysis of these samples demonstrated, by the absence of the characteristic endothermic peaks of fusion of PNTNa and PNTH, that complexation had effectively occurred. The PNTH- HP β -CD 1:1 inclusion complex was extremely deliquescent. Powder X-ray diffractograms of the PNTNa: HP β -CD 1:1 inclusion compound proved it to have an amorphous solid structure.

Conclusions

- 1) Phase-solubility studies have shown that with all three CDs used, a notable increase in the apparent solubility of PNTH in phosphate buffer solution was observed.
- 2) Inclusion complexation was not achieved through kneading.
- 3) Freeze-drying permitted the preparation of an amorphous solid phase with HP β -CD and PNTNa from their aqueous solution.

Claims

1. Inclusion complex formed of pantoprazole, a salt of pantoprazole with a base, an enantiomer of pantoprazole or a salt of an enantiomer of pantoprazole and cyclodextrin.
2. Inclusion complex according to claim 1 formed of pantoprazole sodium sesquihydrate (= pantoprazole sodium x 1.5 H₂O), (-)-pantoprazole sodium sesquihydrate, pantoprazole magnesium dihydrate.
3. Inclusion complex according to claim 1 or 2, wherein the cyclodextrin is β -cyclodextrin.
4. Method for preparation of an inclusion complex according to any of claims 1 to 3 by reacting pantoprazole with the cyclodextrin in a suitable solvent.
5. Method according to claim 4, wherein the solvent is essentially ethanol.
6. Inclusion complex obtainable according to claim 4.
7. Administration form comprising an inclusion complex according to any of claims 1 to 3 together with suitable pharmaceutical auxiliaries.
8. Inclusion complex according to any of claims 1 to 3 for the treatment or prophylaxis of diseases of disorders originating from increased gastric acid secretion.

1103EPORD02 03022

Abstract

An inclusion complex formed from pantoprazole and cyclodextrin is described.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.